Ventricular arrhythmias and sudden death events following acalabrutinib initiation

Similar to ibrutinib before it, there is increasing awareness of the risk of ventricular arrhythmias with acalabrutinib. In a cohort of 290 consecutively treated patients there was a 8.2 increased relative risk of developing a VA compared to non-BTKi treated patients. We will need more long term f/u as acala becomes more popular.

Read the full article here

Related Articles